Literature DB >> 32466880

Lessons From MAVERICK-HCM: The Need for Less Speed.

Jane E Wilcox1, Elizabeth M McNally2.   

Abstract

Entities:  

Keywords:  N-terminal pro-B-type natriuretic peptide (NT-proBNP); cardiac troponin I (cTnI); clinical study; hypertrophic cardiomyopathy; mavacamten

Mesh：

Substances：

Year:  2020        PMID： 32466880      PMCID： PMC7469939          DOI： 10.1016/j.jacc.2020.04.017

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  9 in total

1.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.

Authors:  Eric M Green; Hiroko Wakimoto; Robert L Anderson; Marc J Evanchik; Joshua M Gorham; Brooke C Harrison; Marcus Henze; Raja Kawas; Johan D Oslob; Hector M Rodriguez; Yonghong Song; William Wan; Leslie A Leinwand; James A Spudich; Robert S McDowell; J G Seidman; Christine E Seidman
Journal:  Science       Date:  2016-02-05       Impact factor: 47.728

2.  Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.

Authors:  Robert L Anderson; Darshan V Trivedi; Saswata S Sarkar; Marcus Henze; Weikang Ma; Henry Gong; Christopher S Rogers; Joshua M Gorham; Fiona L Wong; Makenna M Morck; Jonathan G Seidman; Kathleen M Ruppel; Thomas C Irving; Roger Cooke; Eric M Green; James A Spudich
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-13       Impact factor: 11.205

3.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

4.  Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.

Authors:  Stephen B Heitner; Daniel Jacoby; Steven J Lester; Anjali Owens; Andrew Wang; David Zhang; Joseph Lambing; June Lee; Marc Semigran; Amy J Sehnert
Journal:  Ann Intern Med       Date:  2019-04-30       Impact factor: 25.391

5.  Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.

Authors:  Carolyn Y Ho; Matthew E Mealiffe; Richard G Bach; Mondira Bhattacharya; Lubna Choudhury; Jay M Edelberg; Sheila M Hegde; Daniel Jacoby; Neal K Lakdawala; Steven J Lester; Yanfei Ma; Ali J Marian; Sherif F Nagueh; Anjali Owens; Florian Rader; Sara Saberi; Amy J Sehnert; Mark V Sherrid; Scott D Solomon; Andrew Wang; Omar Wever-Pinzon; Timothy C Wong; Stephen B Heitner
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

6.  Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin.

Authors:  John A Rohde; Osha Roopnarine; David D Thomas; Joseph M Muretta
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-17       Impact factor: 11.205

7.  Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes.

Authors:  Lorenzo Alamo; James S Ware; Antonio Pinto; Richard E Gillilan; Jonathan G Seidman; Christine E Seidman; Raúl Padrón
Journal:  Elife       Date:  2017-06-13       Impact factor: 8.140

8.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Christopher N Toepfer; Amanda C Garfinkel; Gabriela Venturini; Hiroko Wakimoto; Giuliana Repetti; Lorenzo Alamo; Arun Sharma; Radhika Agarwal; Jourdan F Ewoldt; Paige Cloonan; Justin Letendre; Mingyue Lun; Iacopo Olivotto; Steve Colan; Euan Ashley; Daniel Jacoby; Michelle Michels; Charles S Redwood; Hugh C Watkins; Sharlene M Day; James F Staples; Raúl Padrón; Anant Chopra; Carolyn Y Ho; Christopher S Chen; Alexandre C Pereira; Jonathan G Seidman; Christine E Seidman
Journal:  Circulation       Date:  2020-01-27       Impact factor: 29.690

9.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).

Authors:  Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Allison L Cirino; Jonathan C Fox; Neal K Lakdawala; James S Ware; Colleen A Caleshu; Adam S Helms; Steven D Colan; Francesca Girolami; Franco Cecchi; Christine E Seidman; Gautam Sajeev; James Signorovitch; Eric M Green; Iacopo Olivotto
Journal:  Circulation       Date:  2018-08-23       Impact factor: 29.690
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.